Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Published byEllen Waters Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"— Presentation transcript:

1 Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.174
Figure 3 Progression of stage of acute kidney injury is associated with significantly worse survival Figure 3 | Progression of stage of acute kidney injury is associated with significantly worse survival. *Three patients were initiated on dialysis on the day of enrollment. Abbreviation: AKIN, Acute Kidney Injury Network. Modified with permission from Wiley © Belcher, J. M. et al. Hepatology 57, 753–762 (2013).33 modified with permission from Wiley © Belcher, J. M. et al. Hepatology 57, 753–762 (2013)33 Wong, F. (2015) The evolving concept of acute kidney injury in patients with cirrhosis Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"

Similar presentations

Figure 1 Proposed risk stratification for patients with NAFLD

Figure 1 Proposed risk stratification for patients with NAFLD
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 7 Management algorithm for patients with ACLF

Figure 7 Management algorithm for patients with ACLF
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis

Figure 2 The microbiome–gut–brain axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 2 The concept of the hepatic reserve and ACLF

Figure 2 The concept of the hepatic reserve and ACLF
Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Similar presentations

Ads by Google